Business Context and Reporting Period
Company: Mesoblast Limited (ASX: MSB; Nasdaq: MESO)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended December 31, 2021
Business Overview: Mesoblast is a clinical-stage biotechnology company developing allogeneic cellular medicines based on mesenchymal lineage adult stem cells. Key product candidates include remestemcel-L (for pediatric steroid-refractory acute Graft versus Host Disease, ARDS, and IBD) and rexlemestrocel-L (for chronic heart failure and chronic low back pain). The company generates revenue primarily through licensing agreements and royalties from partners such as JCR Pharmaceuticals and Takeda.
Key Financial Metrics (Six Months Ended Dec 31, 2021)
| Metric | Value (USD) |
|---|---|
| Total Revenue | $5.98 million |
| Net Loss | $(48.59) million |
| Loss Per Share (Basic & Diluted) | $(0.0750) |
| Cash and Cash Equivalents | $94.85 million |
| Total Debt (Borrowings) | $91.75 million |
| Net Debt | $(14.38) million |
| Operating Cash Flow | $(36.42) million |
| Accumulated Deficit | $(696.16) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 69% to $5.98 million from $3.55 million in the prior year period. This was driven by a 38% increase in commercialization revenue (royalties from TEMCELL and Alofisel) and the recognition of $1.17 million in milestone revenue from Takeda for regulatory approval in Japan.
- Expense Reduction: Research & Development expenses decreased 42% to $19.53 million, and Manufacturing Commercialization expenses decreased 23% to $14.13 million, primarily due to reduced third-party costs and product support costs as clinical trial enrollment completed for several programs.
- Debt Refinancing: In November 2021, the company refinanced its senior debt facility with Hercules Capital, replacing it with a new $90.0 million five-year facility from Oaktree Capital Management. The company drew $60.0 million to repay the Hercules loan.
- Warrant Liability: A new warrant liability of $6.06 million was recognized related to the Oaktree debt facility, resulting in a $2.15 million gain from fair value remeasurement during the period.
- Going Concern: Management notes a material uncertainty regarding the company's ability to continue as a going concern, dependent on accessing additional cash inflows (up to $40 million available under loan arrangements) or strategic partnerships.
Guidance, Outlook, and Risks
- Regulatory Outlook: The company is awaiting FDA feedback on remestemcel-L for pediatric SR-aGVHD following a Complete Response Letter in 2020. Positive results were announced for remestemcel-L in ulcerative colitis/Crohn's disease and durable pain reduction for rexlemestrocel-L in chronic low back pain.
- Liquidity Strategy: The company expects to meet forecast expenditure over the next 12 months by drawing on the remaining $30 million tranche of the Oaktree facility (subject to milestones) and/or completing strategic partnerships. No specific financial guidance for future periods was provided.
- Key Risks:
- Regulatory Approval: Failure to obtain FDA approval for remestemcel-L or rexlemestrocel-L would prevent commercialization and revenue generation.
- Capital Requirements: The company anticipates continuing to incur significant losses and will require additional financing to fund operations and development.
- Manufacturing: Reliance on third-party contract manufacturers (Lonza) in Singapore, which faces potential disruptions from the COVID-19 pandemic and supply chain constraints.
- Legal Proceedings: A securities class action lawsuit regarding the FDA Complete Response Letter has been settled in principle for $2.0 million, to be paid by the company's insurer.
Investor Verification Checklist
- Cash Runway: Verify the timeline for cash depletion given the $94.85 million cash balance and $36.42 million operating cash outflow over six months.
- Debt Covenants: Confirm compliance with the Oaktree facility's minimum unrestricted cash balance covenant of $35.0 million in the U.S.
- Regulatory Milestones: Monitor FDA communications regarding the remestemcel-L BLA resubmission and the Phase 3 trial design for rexlemestrocel-L in chronic low back pain.
- Revenue Sustainability: Assess the sustainability of royalty revenue from JCR and Takeda, noting that milestone revenue is non-recurring.
- Going Concern Status: Review the specific milestones required to draw the remaining $30 million from the Oaktree facility and the likelihood of achieving them.